Welcome to our dedicated page for Inspiremd news (Ticker: NSPR), a resource for investors and traders seeking the latest updates and insights on Inspiremd stock.
InspireMD, Inc. (NSPR) is a medical device company whose news flow centers on its CGuard® Prime carotid stent system and proprietary MicroNet™ mesh technology for stroke prevention. Company press releases and SEC filings describe InspireMD as the developer of CGuard® Prime for the treatment of carotid artery stenosis, with a focus on making its products a standard approach in carotid stenting.
News about InspireMD often covers clinical milestones and peer-reviewed publications. For example, the company announced that results from its C-GUARDIANS pivotal trial of the CGuard® Prime carotid stent system were published in the Journal of the American College of Cardiology, with data showing low rates of disabling stroke or myocardial infarction through 30 days and low ipsilateral stroke rates through one year. InspireMD has also highlighted external clinical evidence such as the CREST-2 study in the New England Journal of Medicine, which it views as supportive of carotid artery stenting combined with medical therapy.
Investors following NSPR can also expect updates on regulatory and commercial developments. Recent filings report FDA PMA approval for the CGuard Prime Carotid Stent System in the United States and subsequent announcements of a U.S. commercial launch. Quarterly earnings releases describe the impact of CGuard Prime on revenue and provide commentary on procedure volumes and expansion of the company’s commercial team.
Additional news items include capital-raising transactions, such as private placements and warrant exercises, as well as changes in board composition and senior medical leadership. Together, these updates give readers insight into InspireMD’s clinical progress, regulatory status, commercialization efforts, and corporate governance. This page aggregates such NSPR news so readers can review the company’s key announcements in one place.
InspireMD, Inc. (NSPR) has appointed Shane Gleason as General Manager of North America and Vice President of Global Marketing. Gleason brings extensive experience in vascular interventions and successful product launches, essential for the company's growth. As InspireMD nears the completion of its C-Guardian U.S. IDE clinical trial, Gleason's expertise is expected to aid in transitioning to U.S. market readiness. He aims to leverage InspireMD's CGuard EPS and new products like the SwitchGuard TCAR system for a successful market entry. The company focuses on making its proprietary MicroNet technology the industry standard for carotid stenting.
InspireMD has launched a video series titled "12 Days of Carotid Stenting," featuring top vascular specialists discussing the carotid treatment market's trends. Available from November 28, 2022, the series aims to highlight the advantages of the CGuard™ Embolic Prevention Stent System for stroke prevention. CEO Marvin Slosman emphasized the series' role in showcasing technology differentiation and the shift towards stenting practices over surgical interventions. The initiative supports InspireMD's goal of establishing CGuard™ as the global standard for treating carotid artery disease.
InspireMD (NSPR) announced its participation in the 2022 VEITH Symposium from November 15 to 19 in New York City. CEO Marvin Slosman highlighted the significance of the event for promoting the CGuard™ Embolic Prevention System (EPS), emphasizing its growing clinical data advantages over competitors. Multiple presentations will showcase clinical results and long-term outcomes of CGuard, particularly in carotid artery stenting. This exposure aims to enhance awareness of the technology amongst vascular medicine specialists.
InspireMD announced its third-quarter 2022 results, showcasing a 38.8% year-over-year growth in CGuard™ revenue, reaching $1.43 million. The company sold 2,624 stents, up from 1,709 in 2021. Operating expenses increased 20.7% to $4.98 million, leading to a net loss of $4.53 million or $0.58 per share. A strategic partnership with NAMSA aims to enhance device development. The company continues to progress with its U.S. IDE trial, currently enrolling at 24 sites, and anticipates completion by end of Q1 2023.
InspireMD (Nasdaq: NSPR) will report its Q3 2022 financial results on November 8, 2022, before the markets open. A conference call and webcast will be held at 8:30 a.m. EDT to discuss the results and provide updates on corporate developments. Investors are encouraged to access the webcast 15 minutes prior. The company aims to set industry standards for carotid stenting through its proprietary MicroNet® technology, enhancing patient outcomes and preventing strokes.
InspireMD, Inc. (NASDAQ: NSPR) announced its participation in the 2022 Transcatheter Cardiovascular Therapeutics (TCT) Conference, scheduled from September 16-19, 2022, in Boston, MA. The presentation will focus on the CGuard™ Embolic Prevention System and its effectiveness in treating carotid stenosis-related cerebral injury.
Prof. Piotr Musialek will present on September 17, 2022, at 4:15 pm ET. The study aims to provide insights into the clinical application of their technology, which seeks to enhance outcomes in carotid stenting.
InspireMD, Inc. (NASDAQ: NSPR) has partnered with NAMSA for strategic outsourcing to enhance medical device development and commercialization. This collaboration aims to expedite the launch of InspireMD's CGuard™ Embolic Prevention System for carotid artery disease and stroke prevention. Both companies focus on accelerating clinical development through NAMSA's expertise in navigating regulatory requirements. InspireMD plans to leverage this partnership to advance its MicroNet™ technology, aiming to establish it as a standard in the carotid stenting market.
InspireMD reported a 47.8% growth in CGuard™ revenue year-over-year, achieving $1,505,000 in the second quarter of 2022. This surge in sales volume came from selling 2,602 stent systems compared to 1,623 in Q2 2021. Despite the positive revenue growth, the company's net loss widened to $4,636,000 or $0.59 per share, up from $3,507,000, as operating expenses increased significantly. Total revenue for the first half of 2022 reached $2,714,000, marking a 32.8% rise year-over-year.
InspireMD (Nasdaq: NSPR) will report its second quarter 2022 financial results on August 9, 2022, before market opening. The company, known for the CGuard™ Embolic Prevention Stent System, aims to provide significant clinical advancements in treating carotid artery disease. A conference call will occur at 8:30 a.m. EDT on the same day to discuss these results and corporate updates. InspireMD focuses on ensuring long-term stroke-free outcomes through its proprietary MicroNet® technology.
InspireMD, Inc. (Nasdaq: NSPR) appointed endovascular pioneer Dr. Juan Parodi as a strategic advisor on July 14, 2022. Known for performing the first endovascular repair procedure in 1990, Dr. Parodi brings significant expertise to InspireMD's efforts in stroke prevention. CEO Marvin Slosman emphasized Dr. Parodi's contributions to vascular surgery, particularly with the CGuard™ Embolic Prevention System, which aims to enhance patient outcomes in carotid artery disease. Dr. Parodi's involvement underscores InspireMD's commitment to innovation and clinical performance.